Core B - David Elder The Pathology Core is responsible for the provision of expert pathological assistance in the interpretation of histological data to the Projects, for the development of immunohistochemical and in situ hybridization methods to enable the identification of antigens or mRNAs in archival and freshly-isolated tissues, and for accrual of residual material not required for diagnosis from human melanomas and nevi for use in the Projects. Expertise in all aspects of the pathological diagnosis and classification of melanocytic neoplasms is provided to the projects on a continuing basis, and is useful in the characterization of experimental models, as well as in the evaluation of expression of novel and experimental markers in benign, intermediate, and malignant melanocytic tumors. The Core personnel are expert in standard immunohistochemical and in situ hybridization techniques, and are very experienced in the workup of novel antibodies and probes. Under previous funding, the Core has been continuously involved in the procurement, prioritization, and provision of tissue, blood, and other biological samples for research projects. Appropriate IRB approved informed consent protocols are used. The Core maintains a shared bank of frozen tissue, and of paraffin blocks and/or sections, from melanocytic tumors, The Core has participated in the production of two tissue microarrays with cooperative groups and has access to slides from these. In addition, the Core is involved in an ongoing basis in the continuing accrual of tissues. These functions are shared with other programs, providing efficiencies that allow this Core to provide a much wider arrange of services and procurement functions than might otherwise be feasible. Biosamples are prioritized through a Tissue Allocation Committee that includes investigators from this program project, as well as from other programs. In this manner, collection, initial processing, storage if necessary, prioritization, distribution, and usage of material in the projects can be reliably tracked and optimized to ensure the best use of scarce tissue resources.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37:
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov :
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386
Ojha, Rani; Leli, Nektaria M; Onorati, Angelique et al. (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356

Showing the most recent 10 out of 144 publications